GAD1 and type 1 diabetes mellitus: In recently published results of this trial, GABA/GAD were administered orally, twice daily, to participants with recent-onset T1D reduced serum glucagon in fasting and meal-stimulated conditions, but did not meet the primary endpoint of maintained C-peptide in the participants [34].